Glenmark pioneers Remogliflozin & Vildagliptin fixed dose for type 2 diabetes

Glenmark Pharmaceuticals announced on Tuesday that it has launched a fixed-dose combination (FDC) of its novel, patent-protected Sodium-Glucose co-transporter inhibitors (SGLT2i)- Remogliflozin Etabonate and another commonly used DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor) – Vildagliptin, in India.  

The launch sets Glenmark as the first company in the world to launch Remogliflozin + Vildagliptin fixed-dose combination while India is the first country to get access to this FDC drug. The company received approval from DCGI, the drug approval authority in India for manufacturing & marketing of Remogliflozin + Vildagliptin combination in the late November 2020.   

In India, Glenmark has been at the forefront in providing access to these latest treatments involving SGLT2i and DPP4 inhibitors as they have been emerging as the preferred treatment option for the management of type 2 diabetes.   

At 1.50 pm on Tuesday, the stock of Glenmark Pharmaceuticals was trading at Rs 496.55 per share, down by 0.40 per cent or Rs 2.00 per share. Its 52-week high is Rs 572.70 and the 52-week low is Rs 168 on BSE.